Intralesional Methotrexate for Treatment of Invasive Squamous Cell Carcinomas in a Patient Taking Vemurafenib for Treatment of Metastatic Melanoma

Neoadjuvant intralesional methotrexate in cutaneous squamous cell carcinoma: a comparative cohort study

“…Locally, infiltration achieves higher MTX intracellular concentration in cSCC cells, which are >10 4 times more sensitive to the cytotoxic effect of MTX . The success shown by MTX–il in the treatment of keratoacanthomas both as monotherapy and neoadjuvant to surgery has led to various authors using it in some cSCC cases …”

“…Intralesional methotrexate (MTX–il) has demonstrated utility in the treatment of keratoacanthomas, a controversial entity regarded as a benign counterpart of cSCC . However, there are only three described cases of its use in infiltrating cSCC as neoadjuvant therapy …”

Intralesional methotrexate in dermatology: Diverse indications and practical considerations

“…All lesions resolved and decreased in size, with no recurrence during follow‐up at 8 months 24,25 . Side‐effects were related to pain during injection in one patient 25 …”

“…Three to four injections were required with weekly intervals over three to 4 weeks 24,25 . All lesions resolved and decreased in size, with no recurrence during follow‐up at 8 months 24,25 . Side‐effects were related to pain during injection in one patient 25 …”

“…Two case reports discussed the successful treatment of IL‐MTX for SCC (25 mg/ml). Three to four injections were required with weekly intervals over three to 4 weeks 24,25 . All lesions resolved and decreased in size, with no recurrence during follow‐up at 8 months 24,25 .…”